Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Active ingredients: zoledronic acid
What it is used for
- Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures. - Treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures. - To increase bone mineral density in men with osteoporosis. - To increase bone mineral density in patients with osteoporosis associated with long term glucocorticoid use. - To prevent glucocorticiod-induced bone mineral density loss. - Treatment of Paget's disease of bone.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store below 30 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear colourless solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient zoledronic acid
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Osteoporosis real lives | Garvan Institute of Medical Research
Real life stories of people living with osteoporosis. How they were diagnosed, how they live with disease, and how research has an impact.
Read more on Garvan Institute of Medical Research website
What you need to know about Osteoporosis
1.2 million Australians are affected by osteoporosis, which means that their bones are fragile and at risk of fracture. A further 6.3 million people have low bone density (osteopenia), a possible precursor to osteoporosis. However, as many as 4 out of 5 people with osteoporosis don’t know that they have it and therefore don’t know that they are at risk of fracturing a bone. This is because osteoporosis is a ‘silent’ disease without obvious symptoms.
Read more on Osteoporosis Australia website
Osteoporosis - Australasian Menopause Society
Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis.Peak bone mass is usually reached during a womans 20s to 30s when the skeleton has stopped growing and bones are at their strongest.The female sex hormone oestrogen plays an important role in maintaining bone strength. After menopause oestrogen levels drop and this may result in increased bone loss. The average woman loses up to 10 per cent of
Read more on Australasian Menopause Society website